At the 2023 Asian Para Games opening ceremony, a swimmer raised a torch and lit it — with a prosthetic hand she controlled through signals read from her own nerves and muscles.
The hand was built by BrainCo (强脑科技). Three years later, that same company is knocking on the Hong Kong stock exchange, and the bet it represents is bigger than one product: that non-invasive brain-computer interface (脑机接口) can reach millions without a single surgery.
Key takeaways
- BrainCo confidentially filed for a Hong Kong IPO in January 2026, advised by CICC and UBS — potentially the first listing among Hangzhou's "Six Little Dragons" (杭州六小龙) tech champions.
- It closed a roughly 2 billion yuan (≈ US$286M / HK$2.2B) financing round on 8 January 2026, co-led by IDG Capital and Walden International, with strategic backing from Lens Technology and Will Semiconductor.
- Its BrainRobotics prosthetic hand received U.S. FDA 510(k) clearance (K220002) on 9 September 2022 — reported as the first FDA-cleared non-invasive brain-controlled prosthetic.
- Founded in 2015 by Han Bicheng (韩璧丞) at Harvard Innovation Labs, BrainCo says its products are now used in over 30 countries and regions.
The non-invasive wager
Most headlines about Chinese BCI go to invasive implants — the coin-sized devices placed under the skull. BrainCo deliberately went the other way. It reads neural and muscle signals through external sensors and wearable hardware, avoiding the operating room entirely.
That choice shapes everything. Non-invasive systems trade raw signal quality for safety, cost and scale. A device you can put on does not need a neurosurgeon, a hospital bed or a regulatory pathway built for implanted medical devices. For rehabilitation, education and consumer wellness, that unlock is the whole point.
BrainCo's flagship is the BrainRobotics intelligent bionic hand, which uses electromyography and EEG signals to give upper-limb amputees dexterous control. Its FDA clearance in September 2022 gave it a rare credential: a regulated-market stamp most BCI startups lack. The company reports the product's price has fallen to roughly a tenth of comparable imported devices, widening access.
From lab to IPO
BrainCo's origins still shape its strategy. Founder Han Bicheng (韩璧丞), a Harvard brain-science PhD, built the first team inside the Harvard Innovation Labs — the first Chinese team incubated there — before relocating the company to Hangzhou in 2018. That academic root shows in the product map: instead of one heroic implant, a portfolio of wearable EEG headsets, sleep devices and bionic limbs, each aimed at a mass-market use that carries no surgical risk. It is a deliberately different commercial logic from the invasive players, and it is the logic an IPO prospectus has to defend.
The January 2026 financing was large by any neurotech standard: about 2 billion yuan (≈ US$286M / HK$2.2B), ranked by Chinese media as the second-largest single BCI financing globally after Neuralink. Strategic investors Lens Technology and Will Semiconductor are not passive holders — Lens, for instance, takes on core hardware-module manufacturing, the kind of supply-chain muscle a scaling hardware company needs.
The confidential Hong Kong filing, first reported by Bloomberg on 12 January 2026, puts BrainCo on track to become the first publicly listed member of Hangzhou's "Six Little Dragons" — the cohort that also includes AI lab DeepSeek and robotics firm Unitree. As of late 2026 no hearing or pricing had been reported; the prospectus remains non-public.
Beyond the prosthesis
BrainCo has pushed the same non-invasive stack into adjacent markets. Its Focus headband brings EEG-based attention training into schools. Sleep and wellness devices target the consumer side. In May 2026 it launched a smart-prosthetics program with Hong Kong Polytechnic University and the Hong Kong SAR government, donating bionic limbs to 60 local amputees.
The company's stated ambition is broad: within five to ten years, help one million limb-disabled people regain daily life through neuro-controlled prosthetics, and improve outcomes for ten million (千万) patients dealing with autism, ADHD, Alzheimer's and insomnia.
Honest limitations
"Non-invasive BCI" still means fighting weak, noisy signals. Reading intention through skin and bone is fundamentally harder than reading it from an electrode on the brain, and no amount of funding closes that physics gap for every task. The bionic hand, notably, relies heavily on muscle (EMG) signals at the limb — it is BCI-adjacent rather than pure cortical decoding.
The IPO is filed, not done. Confidential submission is an early, reversible step; market conditions and regulatory review will decide timing and even whether it proceeds. The 2-billion-yuan round and the US$1.3B valuation reported in 2025 pre-IPO talks are snapshots, not guarantees of listed-market value.
And the "first," "unicorn," "largest" framing in Chinese coverage should be read as promotional context. What is solid: a real FDA clearance, real products in 30-plus markets, and a credible manufacturing partnership.
What readers can do now
- Investors should distinguish BrainCo's non-invasive, hardware-scaling model from invasive clinical-BCl players — different risk profiles, different time horizons to revenue.
- Clinicians and rehabilitation centers can evaluate FDA-cleared non-invasive prosthetics and compare cost and training burden against implanted alternatives for suitable patients.
- Consumers curious about BCI can start with a reputable consumer EEG headband to learn the basics — just expect modest, well-bounded capabilities rather than science-fiction control.